CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Sun Yat-sen University
Kyowa Kirin Co., Ltd.
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Caja Costarricense de Seguro Social
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Eli Lilly and Company
Fondazione Italiana Linfomi - ETS
University of Utah
Shanghai Jiao Tong University School of Medicine
Shanghai Jiao Tong University School of Medicine
Institute of Hematology & Blood Diseases Hospital, China
University of Michigan Rogel Cancer Center
Nantes University Hospital
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Fondazione Italiana Linfomi - ETS
Comenius University
Centre Hospitalier Universitaire de Nice
Virogen Biotechnology Inc.
Washington University School of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Wisconsin, Madison
The Royal Wolverhampton Hospitals NHS Trust
Mayo Clinic
University of Miami
Nurix Therapeutics, Inc.
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Affiliated Hospital to Academy of Military Medical Sciences
Nurix Therapeutics, Inc.
Dana-Farber Cancer Institute
University of Nebraska
Arovella Therapeutics Ltd
St. Justine's Hospital
New York State Psychiatric Institute
University of Arizona
St. Jude Children's Research Hospital
Assiut University
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
AstraZeneca